Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Janne Marvola is active.

Publication


Featured researches published by Janne Marvola.


European Journal of Pharmaceutics and Biopharmaceutics | 2004

Gamma scintigraphic evaluation of the fate of microcrystalline chitosan granules in human stomach.

Mia Säkkinen; Janne Marvola; Hanna Kanerva; Kai Lindevall; Maija Lipponen; Tommi Kekki; Aapo Ahonen; Martti Marvola

In several reports of in vitro studies it has been suggested that the mucoadhesive chitosans could be of value in preparing gastro-retentive formulations. The aim of this study was to obtain direct in vivo evidence of whether microcrystalline chitosan (MCCh) formulations acted as gastro-retentive systems in humans. Neutron-activation-based gamma scintigraphy was used to study gastric residence times of MCCh granules in healthy male volunteers. Possible effects of neutron irradiation on the properties of the MCCh granules were studied in advance, in vitro. In vivo gamma scintigraphic evaluations were carried out with the subjects in a fasted state, using granules containing 95% (F1) or 40% (F2) of MCCh of molecular weight 150 kDa. Reference formulation (F3) was lactose granules. The reference granules passed rapidly from the stomach (mean t50% 0.5+/-0.3 h (n=5)). MCCh in granules prolonged gastric residence times of the formulations in only a few cases (in one volunteer in the F1 group (n=4) and in two volunteers in the F2 group (n=5)). Maximum individual t50% values were 2.1 h (F1) and 2.3 h (F2). It was concluded that the in vivo mucoadhesion of MCCh formulations is erratic, and that the formulations studied are not reliable gastro-retentive drug delivery systems.


European Journal of Pharmaceutics and Biopharmaceutics | 2004

Scintigraphic verification of adherence of a chitosan formulation to the human oesophagus

Mia Säkkinen; Janne Marvola; Hanna Kanerva; Kai Lindevall; Aapo Ahonen; Martti Marvola

It is well known that adherence of a drug product, e.g. a gelatine capsule, to the oesophagus can cause oesophageal injury, which can be severe if the medicinal agent has corrosive properties. In a recent study we investigated by means of gamma scintigraphy whether chitosan granules dispensed in gelatine capsules had gastro-retentive properties. In one of ten volunteers the formulation lodged in the oesophagus. This case is reported here. The capsule adhered initially to the distal oesophagus. The capsule shell had started to disintegrate within 5 min, with some radioactivity detectable in the stomach. However, about two thirds of the radioactivity remained detectable in the oesophageal region for 1.75 h. This could be explained on the basis that there had been adherence not only of the gelatine shell but also of chitosan granules to the oesophageal mucosa. In evaluating potential for causing oesophageal injury it is not enough to consider only the mucoadhesive properties of the outermost layer of a drug product, because the filler may also have such properties. When new excipient materials are introduced, evaluation of their mucoadhesive tendencies is important.


Drug Development and Industrial Pharmacy | 2010

Computational prediction of local drug effect on carcinogenic acetaldehyde in the mouth based on in vitro/in vivo results of freely soluble l-cysteine

Alma Kartal; Janne Marvola; Jenni Matheka; Marikki Peltoniemi; Mia Sivén

Background: The computational models for predicting oral drug absorption in humans using in vitro and in vivo data have been published. However, only a limited number of studies are available on the prediction of local drug efficacy in the mouth using computational models. Aim: The goal of this study was to develop a simulation model for prediction of drug amount and effect on carcinogenic acetaldehyde in the mouth. Methods: The model was based partly on our previous studies in which we showed in vivo that l‐cysteine-containing tablets can eliminate carcinogenic salivary acetaldehyde in the mouth during smoking. To develop as informative a model as possible, we also investigated whether a lower saliva pH (4.7) can affect the freely soluble l-cysteine dissolution rate and cysteine stability profile in the mouth, compared to the normal saliva pH of 7.4. Results: Stability of the active drug is not pH dependent and thus users with normal, healthy saliva pH and those with lower pH can benefit from cysteine-containing products. The simulated saliva profiles of l-cysteine and acetaldehyde corresponded to the in vivo results. Conclusions: The model developed can be used as an alternative tool to obtain faster and cheaper answers on how freely soluble drugs affect local conditions in the mouth. Because tobacco smoke contains more than 60 carcinogenic compounds, the model developed can offer a new view in eliminating or reducing not only one toxic compound from smoke but also many others compounds using only one formulation containing various active compounds.


International Journal of Pharmaceutics | 2006

Are chitosan formulations mucoadhesive in the human small intestine?: An evaluation based on gamma scintigraphy

Mia Säkkinen; Janne Marvola; Hanna Kanerva; Kai Lindevall; Aapo Ahonen; Martti Marvola


International Journal of Pharmaceutics | 2008

Neutron activation based gamma scintigraphic evaluation of enteric-coated capsules for local treatment in colon.

Tuuli Marvola; Janne Marvola; Hanna Kanerva; Aapo Ahonen; Kai Lindevall; Martti Marvola


European Journal of Pharmaceutical Sciences | 2004

Gamma scintigraphic evaluation of the fate of hydroxypropyl methylcellulose capsules in the human gastrointestinal tract.

Outi Honkanen; Janne Marvola; Hanna Kanerva; Kai Lindevall; Maija Lipponen; Tommi Kekki; Aapo Ahonen; Martti Marvola


International Journal of Pharmaceutics | 2004

Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet® constant-release drug delivery system

Janne Marvola; Hanna Kanerva; Lillian Slot; Maija Lipponen; Tommi Kekki; Heikki Hietanen; Sirpa Mykkänen; Kari Ariniemi; Kai Lindevall; Martti Marvola


European Journal of Pharmaceutical Sciences | 2007

Compartmental absorption and transit model of human small intestine and colon based on a pharmacoscintigraphic in vivo study with caffeine

Janne Marvola; Marjo Yliperttula; Arto Urtti


European Journal of Pharmaceutical Sciences | 2008

Developing an extended compartmental absorption and transit model for per oral controlled drug delivery

Janne Marvola; Arto Urtti; Marjo Yliperttula


European Journal of Pharmaceutical Sciences | 2007

Site-specific l-cysteine formulations for prevention of cancer in stomach and colon

Tuuli Marvola; S. Mahlamäki; P. Kreutzwald; Janne Marvola; Hanna Kanerva; Aapo Ahonen; Peep Veski; Martti Marvola

Collaboration


Dive into the Janne Marvola's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Aapo Ahonen

University of Helsinki

View shared research outputs
Top Co-Authors

Avatar

Maija Lipponen

VTT Technical Research Centre of Finland

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tommi Kekki

VTT Technical Research Centre of Finland

View shared research outputs
Top Co-Authors

Avatar

Arto Urtti

University of Eastern Finland

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alma Kartal

University of Helsinki

View shared research outputs
Researchain Logo
Decentralizing Knowledge